15:00 EDT Abbott (ABT) owes $17M in damages in baby formula trial, Bloomberg reports
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- William Blair health diagnostics analyst holds analyst/industry conference call
- Abbott Laboratories: Solid Q1 Setup and Resilient MedTech/Diagnostics Support Path to 2026 Targets Amid Manageable Geopolitical Headwinds
- Abbott price target raised to $144 from $142 at Barclays
- Abbott price target lowered to $134 from $138 at Evercore ISI
- Abbott price target lowered to $131 from $140 at BTIG